Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
KRBP | US
-0.10
-8.33%
Healthcare
Biotechnology
30/06/2024
21/10/2024
1.10
1.20
1.20
1.10
Kiromic BioPharma Inc. an artificial intelligence driven allogeneic cell therapy company engages in developing the multi-indication allogeneic T cell therapies that exploits the natural potency of the Gamma Delta T cell (GDT) to target solid tumors. The company develops ALEXIS-ISO-1 an allogeneic GDT therapy product that targets an isoform of mesothelin; and ALEXIS-PRO-1 an allogeneic GDT therapy product that targets PD-L1. It has license agreements with CGA 369 Intellectual Holdings Inc. and Longwood University as well as a research and development collaboration agreement with Molipharma S.R.L. The company also has strategic alliance agreement with Leon Office (H.K.) Ltd. The company was formerly known as Kiromic Inc. and changed its name to Kiromic BioPharma Inc. in December 2019. Kiromic BioPharma Inc. was founded in 2006 and is headquartered in Houston Texas.
View LessLow Debt to Equity (< 0.25)
Strong Sharpe Ratio (> 1.2)
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Rich in Valuation (Price to Book > 8)
Bearish: Increased Volatility (6-month > 1-month volatility)
10 days
245.9%1 month
172.0%3 months
239.2%6 months
181.1%-
-
11.55
-2.59
1.07
-0.13
-
-
-20.11M
1.70M
1.70M
-
-
-
-
-1.13K
1.45
6.82
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
0.21
Range1M
0.61
Range3M
1.41
Rel. volume
0.32
Price X volume
331.10
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Panbela Therapeutics Inc | PBLA | Biotechnology | 0.3354 | 1.76M | 5.14% | 0.00 | -39.69% |
Innovation Pharmaceuticals Inc | IPIX | Biotechnology | 0.003 | 1.56M | 200.00% | n/a | 20.48% |
CohBar Inc | CWBR | Biotechnology | 0.5 | 1.45M | 0.00% | n/a | 0.00% |
Arch Therapeutics Inc | ARTH | Biotechnology | 0.3002 | 1.33M | 0.00% | n/a | 0.00% |
TC BioPharm (Holdings) plc American Depositary Shares | TCBP | Biotechnology | 2.27 | 1.30M | -55.14% | n/a | 131.42% |
Evofem Biosciences Inc | EVFM | Biotechnology | 0.0092 | 923.03K | -8.00% | 0.00 | 0.00% |
Seelos Therapeutics Inc | SEEL | Biotechnology | 1.13 | 832.04K | 11.88% | 0.00 | -36.10% |
International Stem Cell Corporation | ISCO | Biotechnology | 0.06 | 480.26K | 0.00% | n/a | 0.00% |
NexImmune Inc. Common Stock | NEXI | Biotechnology | 0.2514 | 350.62K | -23.82% | n/a | 0.00% |
Vaxxinity Inc. Class A Common Stock | VAXX | Biotechnology | 0.002 | 253.57K | 0.00% | n/a | 113.12% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.011 | 1.01M | 10.00% | n/a | -37.05% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -0.13 | 0.53 | Cheaper |
Ent. to Revenue | - | 3,967.00 | - |
PE Ratio | - | 41.03 | - |
Price to Book | 11.55 | 15.55 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 239.19 | 72.80 | Riskier |
Debt to Equity | -2.59 | -1.23 | Cheaper |
Debt to Assets | 1.07 | 0.25 | Expensive |
Market Cap | 1.70M | 3.66B | Emerging |